GT Biopharma, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About GT Biopharma, Inc.

GT Biopharma, Inc. (NASDAQ: GTBP) is a United States-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. The company is focused on immuno-oncology and is developing therapies built around its proprietary TriKE® platform, a natural killer (NK) cell engager approach designed to help the immune system identify and attack cancer cells. For investors, GT Biopharma should be viewed as a development-stage biotech story in which the main drivers are clinical execution, platform differentiation, and access to capital rather than current commercial revenue. ([gtbiopharma.com](https://www.gtbiopharma.com/?utm_source=openai)) GT Biopharma has gone through several corporate iterations over time before evolving into its current oncology-focused profile. SEC filings describe the company as a Delaware corporation with earlier legacy names, while its strategic repositioning was materially advanced by the 2017 merger with Georgetown Translational Pharmaceuticals. Its headquarters are in San Francisco, California, placing it in one of the most important biotechnology hubs in the United States. ([gtbiopharma.com](https://www.gtbiopharma.com/news-media/press-releases/detail/124/gt-biopharma-inc-announces-closing-of-oxis-international?utm_source=openai)) Operationally, the company’s core business is the development of TriKE®-based drug candidates across oncology indications. Two programs have recently attracted the most attention: GTB-3650, which is being developed for CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted NK cell engager for solid tumors. GT Biopharma describes the platform as combining tumor targeting with NK-cell activation through CD16, while also incorporating an IL-15 component intended to stimulate NK-cell proliferation and activation. ([gtbiopharma.com](https://www.gtbiopharma.com/product-pipeline/overview?utm_source=openai)) In competitive terms, GT Biopharma remains a small, highly specialized oncology biotech competing in a crowded field that includes much larger immunotherapy and oncology developers. Its investment case rests on whether the TriKE® platform can generate clinically meaningful differentiation and eventually translate into value-creating data readouts. Like most micro-cap clinical biotechs, it is still dependent on external financing and has not yet built a recurring commercial business. ([ir.gtbiopharma.com](https://ir.gtbiopharma.com/press-releases/detail/306/gt-biopharma-reports-full-year-2025-financial-results?utm_source=openai)) Recent developments are especially relevant. In January 2026, the company announced submission of the GTB-5550 IND, and in early February 2026 it disclosed FDA clearance of that IND, with a phase 1 basket trial expected to begin in mid-2026. In March 2026, GT Biopharma reported full-year 2025 results and said it had about $9 million of pro forma cash as of January 31, 2026, which it expects to fund operations through the fourth quarter of 2026. These updates underscore a pre-commercial biotech with meaningful clinical milestones ahead, but also with continuing financing and execution risk. ([ir.gtbiopharma.com](https://ir.gtbiopharma.com/press-releases/detail/306/gt-biopharma-reports-full-year-2025-financial-results?utm_source=openai))